Highlights Aldeyra Therapeutics, Inc.

Equities

ALDX

US01438T1060

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-21 pm EDT			5-day change	1st Jan Change
3.94 ^USD	-2.23%		-5.52%	+12.25%

May. 08	Aldeyra Therapeutics Enrolls First Patient in Phase 3 Dry Eye Chamber Study	MT
May. 08	Aldeyra Therapeutics, Inc. Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye Disease	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Aldeyra Therapeutics Enrolls First Patient in Phase 3 Dry Eye Chamber Study	May. 08	MT
Aldeyra Therapeutics, Inc. Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye Disease	May. 08	CI
Aldeyra Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 02	CI
Aldeyra Therapeutics, Inc. Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye Disease	Mar. 28	CI
Aldeyra Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 07	CI
Aldeyra Therapeutics Provides Clinical and Regulatory Update and Announces Advancement of Rasp Platform in Systemic and Retinal Inflammatory Diseases	Jan. 04	CI
Aldeyra Therapeutics, Inc. and Abbvie to Enter into the Co-Development, Co-Commercialization and License Agreement	Dec. 21	CI
Aldeyra Therapeutics, Inc. Announces Positive Top-Line Results from A Phase 2 Clinical Trial of ADX-629 in Patients with Atopic Dermatitis	Dec. 19	CI
Aldeyra Therapeutics, Inc. Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Dry Eye Disease	Nov. 27	CI
Aldeyra Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 03	CI
Aldeyra Says FDA Finds 'Substantive Review Issues' in NDA for Dry Eye Disease Treatment; Shares Drop	23-10-16	MT
Aldeyra Therapeutics, Inc. Announces Update of U.S. Food and Drug Administration Relating to the New Drug Application for Reproxalap for the Treatment of the Signs and Symptoms of Dry Eye Disease	23-10-16	CI
Aldeyra Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-03	CI
Aldeyra Therapeutics, Inc. Announces Positive Top-Line Results from the Phase 2 Clinical Trial of Adx-629 in Patients with Chronic Cough	23-06-27	CI
Aldeyra Therapeutics Announces Statistically Significant Reduction in Cough Frequency in Phase 2 Clinical Trial of ADX--629 in Patients with Chronic Cough	23-06-27	CI
Aldeyra Therapeutics Stock Down 24% After FDA Rejects Eye Cancer Treatment	23-06-21	DJ
Aldeyra Therapeutics Provides Regulatory Update on ADX-2191	23-06-21	CI
Aldeyra Therapeutics, Inc. Announces Achievement of Statistical Significance for Primary Endpoint and All Secondary Endpoints in Phase 3 INVIGORATE--2 Trial of Reproxalap in Allergic Conjunctivitis	23-06-15	CI
Aldeyra Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-04	CI
Aldeyra Therapeutics, Inc. Completes Enrollment in Phase 2 Clinical Trial of ADX 629 in Chronic Cough	23-03-30	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Aldeyra Therapeutics, Inc.

Equities

ALDX

US01438T1060

Highlights

Filters